Abstract 496P
Background
Indication for treatment with osimertinib after first/second generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance depends on T790M mutation detected by re-biopsy. REMEDY trial consisting many cases using plasma biopsy revealed osimertinib introduction rate of approximately 25 percent in EGFR-mutant non-small cell lung cancer (NSCLC) patients pretreated with first/second generation EGFR-TKIs. The aim of study is to analyze the data on clinical practice of our hospital, where histological re-biopsy is actively carried out multiple times.
Methods
We retrospectively reviewed our electronic medical records of EGFR-mutant NSCLC patients to examine osimertinib introduction rate and associated outcomes.
Results
Among 95 patients with EGFR-mutant NSCLC, 73 patients received first/second generation EGFR-TKIs. Of 57 progressive disease patients, 50 patients (57/50: 87%) underwent re-biopsy. T790M was detected in 36 patients (36/50: 72%) and osimertinib was introduced in 35 patients (35/50: 70%). Among 36 patients harboring T790M mutation: histological re-biopsy was performed in 21 patients (21/36: 58%); cytology in 12 patients (12/36: 33%); blood biopsy in three patients (3/36: 8.3%). T790M was detected by first re-biopsy in 14 patients (14/36: 39%), and by second or subsequent re-biopsy 22 patients (22/36: 61%). The median overall survival (OS) in osimertinib induction patients was not reached (95% CI, 64.2-not reached) while in non- osimertinib patients median OS was 92.9 months (95% CI, 22.5-not reached) (p = 0.0173). Five year survival rates were 77% and 52%, respectively.
Conclusions
Higher osimertinib introduction rate was achieved by multiple repeated re-biopsy after first/second generation EGFR-TKIs, and its high introduction rate could contribute to better prognosis of EGFR-mutant NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kobe Minimally Invasive Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Segmental mandibulectomy without reconstruction
Presenter: Yohei Morishita
Session: Poster display session
Resources:
Abstract
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract